NEWARK, CA / ACCESSWIRE / April 25, 2016 / CymaBay Therapeutics Inc. (CBAY) a biopharmaceutical company focused on developing therapies to treat metabolic diseases, including serious rare and orphan disorders, recently provided corporate highlights and announced financial results for the quarter and year ended December 31, 2015. “We have made significant progress during the last quarter in advancing the development of our two key clinical assets,” said Harold Van Wart, President and Chief Executive Officer of CymaBay. “Earlier in March, we reported some encouraging top-line data from our pilot Phase 2 study in patients with homozygous familial hypercholesterolemia. Analysis of the data showed that MBX-8025 demonstrated the ability to lower LDL-Cholesterol in a majority of patients, despite raising PCSK9 levels. We are evaluating the feasibility of conducting a second pilot study in combination with a PCSK9 inhibitor to assess whether the reductions in LDL-C can be amplified by neutralizing PCSK9.”
With the recent rally slowing down, what does the future hold for CBAY?
For a more detailed research report with analyst comments on CymaBay Therapeutics Inc. (CBAY) please follow the link. There is no cost obligation required to view analyst brief:https://broadstreetalerts.com/cymabay-therapeutics-inc/.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the subject company in this report to be materially different from the statements made herein.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. Information in this release is fact checked and produced on a best efforts basis by Robert Borowski. An outsourced research services provider represented by Robert Borowski, provided Broad Street Alerts this article or report. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. Broad Street Alerts is not entitled to veto, interfere or alter the articles, documents or report once created and reviewed by the outsourced research provider represented by Robert Borowski. The subject Company has not compensated Broad Street Alerts or Robert Borowski for the creation or dissemination of this report. Broad Street Alerts is the party responsible for issuing the press release and for hosting the full analyst report on Broad Street Alerts website. Robert Borowski is the author of research report. This information is submitted to increase awareness for the Broad Street Alerts brand to the investing public.
If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at admin@broadstreetalerts.com. For any urgent concerns or inquiries, please contact us at admin@broadstreetalerts.com.
NOT FINANCIAL ADVICE
Broad Street Alerts makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Broad Street Alerts is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming Broad Street Alerts has compensated Robert Borowski, up to two hundred fifty dollars for the distribution rights to disseminate analyst report. No liability is accepted by Broad Street Alerts whatsoever for any direct, indirect or consequential loss arising from the use of this document. Broad Street Alerts expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Broad Street Alerts does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Broad Street Alerts
Broad street alerts has not been compensated for the mention of any publicly traded companies in this article nor do we own positions in any of the companies in this article.
